Atomoxetine treatment in children and adolescents with attention-deficit/ hyperactivity disorder and comorbid oppositional defiant disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 44, Issue 3, 2005, Pages 240-248

  Newcorn, Jeffrey H ^a   Spencer, Thomas J ^b   Biederman, Joseph ^b   Milton, Denái R ^c   Michelson, David ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Oppositional defiant disorder

Indexed keywords

ATOMOXETINE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER RATING SCALE IV; CHILD HEALTH QUESTIONNAIRE; CLINICAL GLOBAL IMPRESSIONS SEVERITY OF ADHD SCALE; CLINICAL TRIAL; COMORBIDITY; CONNER PARENT RATING SCALE REVISED SHORT FORM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPPOSITIONAL DEFIANT DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SYMPTOMATOLOGY;

EID: 14544286013     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200503000-00008     Document Type: Article

References (37)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Press
2. August GJ, Realmuto GM, MacDonald AW 3rd, Nugent SM, Crosby R (1996), Prevalence of ADHD and comorbid disorders among elementary school children screened for disruptive behavior. J Abnorm Child Psychol 24:571-595
3. Biederman J, Baldessarini RJ, Wright V, Keenan K, Faraone S (1993), A double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response. J Am Acad Child Adolesc Psychiatry 32: 199-204
4. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS (1989), A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777-784
5. Biederman J, Faraone SV, Monuteaux MC (2002), Differential effect of environmental adversity by gender: Rutter's index of adversity in a group of boys and girls with and without ADHD. Am J Psychiatry 159:1556-1562
6. Biederman J, Newcorn J, Sprich S (1991), Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148:564-577
7. Bymaster FP, Kamer J, Nelson DL et al. (2002), Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
8. Cohen J (1988). Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Erlbaum
9. Conners CK (1997). Conners' Rating Scales: Revised Technical Manual. North Tonawanda, NY: Multi-Health Systems Inc.
10. Conners CK, Casat CD, Gualtieri CT et al. (1996), Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314-1321
11. Connor DF, Barkley RA, Davis HT (2000), A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Bologna) 39: 15-25
12. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH Jr (2002), Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 41:253-261
13. Dunnett CW (1955), A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc 50:1096-1121
14. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998). ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: Guilford
15. Gehlert DR, Schober DA, Hemricke-Luecke SK et al. (1995), Novel halogenated analogs of tomoxetine are potent and selective inhibitors of norepinephrine uptake in brain. Neurochem Int 26:47-52
16. Greene RW, Biederman J, Zerwas S, Monuteaux MC, Goring JC, Faraone SV (2002), Psychiatric comorbidity, family dysfunction, and social impairment in referred youth with oppositional defiant disorder. Am J Psychiatry 159:1214-1224
17. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: United States Department of Health, Education, and Welfare
18. Hechtman L (2000), Assessment and diagnosis of attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:481-498
19. Hunt RD, Arnsten AF, Asbell MD (1995),An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:50-54
20. Hunt RD, Minderaa RB, Cohen DJ (1986), The therapeutic effect of clonidine in attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate. Psychopharmacol Bull 22:229-236
21. Kaufman J, Birmaher B, Brent D et al. (1997), Schedule for Affective Disorders and Schizophrenia for School-Age Children-Ptesent and Lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988
22. Kuhne M, Schachar R, Tannock R (1997), Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 36:1715-1725
23. Landgraf JM, Maunsell E, Speechley KN et al. (1998), Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. Qual Life Res 7: 433-445
24. Michelson D, Allen AJ, Busner AJ, et al. (2002), Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159: 1896-1901
25. Michelson D, Faries D, Wernicke J et al. (2001), Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:e83
26. MTA Cooperative Group (1999a), A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086
27. MTA Cooperative Group (1999b), Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1088-1096
28. Poznanski EO, Mokros HB (1999). Children's Depression Rating Scale (CDRS-R) Revised. Los Angeles: Western Psychological Services
29. Prince JB, Wilens TE, Biederman J et al. (2000), A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10: 193-204
30. Spencer T, Biederman J, Wilens T et al. (1998), Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693-695
31. Stevens J, Quittner AL, Abikoff H (1998), Factors influencing elementary school teachers' ratings of ADHD and ODD behaviors. J Clin Child Psychol 27:406-414
32. Wechsler D (1991). Wechsler Intelligence Scale for Children (WISC-III). San Antonio, TX.: The Psychological Corporation
33. Wilens TE (2004), Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 27:283-301
34. Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T (1993), Nortriptyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32:343-349
35. Wilens TE, Spencer TJ, Biederman J et al. (2001), A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158:282-288
36. Wong DT, Threlkeld PG, Best KL, Bymaster FP (1982), A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 222:61-65
37. World Medical Association (2000), Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. Adopted by the 18th World Medical Association General Assembly, Helsinki, Finland, June 1964 and amended by the 52nd World Medical Association General Assembly, Edinburgh, Scotland, October 2000